OCTOBER 2023LIFE SCIENCES REVIEW 19between vector genome quantity and associated vector-derived gene expression within the same tissues, allowing cleaner and more accurate data processing while consuming less precious animal tissues. Most laboratories today debate the use of traditional qPCR versus dPCR instrumentation for biodistribution and gene expression analysis in cell and gene therapy product studies. NBS has combined the two laboratory instruments and intertwined the best of qPCR and dPCR. "We use dPCR for accurate determination of the concentrations of DNA/RNA standards, and then (RT )qPCR with the digital PCR-titer standards to help with a higher throughput sample analysis," says Haiyan Ma, PhD, Director of Science at NBS. The strategy not only improves preclinical and clinical sample analysis accuracy, but also provides sponsors with the satisfaction of overcoming two obstacles--time limits and financial considerations.NBS scientists have accumulated extensive experience in the gene therapy field since 2008. This knowledge plays a role in the overall study design when sponsors choose NBS as their CRO. For example, thoughtful consideration is taken during the design of primers and TaqMan probes to the target specific sequences within their test material. Scientists perform comprehensive research to ensure the developed primer/probe set is specific to the target sequence with specificity in not only the relevant study-specific species, but other animals including humans. This approach empowers their sponsors to save time and quickly release pharmaceutical products. Since cost is a factor, the heightened operations allow sponsors to secure additional funding sooner. The commitment to supporting sponsors throughout the drug development journey--from the initial discovery phase to clinical trials--is yet another way NBS ensures a seamless and cost-efficient process.NBS's biomolecular analysis, data-driven techniques, and collaborative approach enable sponsors to identify efficient study design initiation and project outcomes. Sponsors can use the data to make well-informed decisions and confidently move toward the best result as NBS' solutions portfolio is built on market research, customer feedback, industry expertise, and strategic planning. Its solutions are process-driven, with clearly defined objectives and a commitment to continual sponsor support.The company offers unmatched expertise through a customized and sponsor-centric approach, proven results, comprehensive sponsor support, quality data, and a focus on building long-term partnerships. These factors collectively make the CRO an ideal choice for potential sponsors seeking a partner to help develop targeted treatments and cures for unmet medical needs. The efficient time management and fostering of a collaboration culture empower its sponsors to overcome time constraints by expediting scheduling and financial considerations through competitive pricing.Through its team of industry-leading scientists, including experts such as Ma and Bell, NBS is on the cusp of expanding its services array by increasing its capacity and capabilities. The company remains dedicated to providing exceptional services to meet the growing need for its cell and gene therapy expertise. NBS has extended its services by offering to include protein sample analysis, utilizing enzyme-linked immunoassays (ELISA) and Meso Scale Discovery (MSD) assays. The company's work culture directly influences the quality of its services and sponsor satisfaction, making it a reputable and sought-after partner in the biomolecular services industry. Our key strength is a team of experienced staff with extensive knowledge in developing and validating various cell and gene therapy testing methods to enhance sponsor therapeutics studiesHaiyan Ma, Ph.D., Director of Science
< Page 9 | Page 11 >